Amy­lyx's Re­lyvrio pulls in $71M in rev­enue

Amy­lyx’s ALS drug Re­lyvrio brought in $71.4 mil­lion in rev­enue in the first quar­ter of the year, far sur­pass­ing ex­pec­ta­tions for a CNS ther­a­py ap­proved less than a year ago.

Re­lyvrio is Amy­lyx’s on­ly ap­proved prod­uct. It’s avail­able in the US and Cana­da, where it goes by the name Al­bri­oza, and the com­pa­ny said it ex­pects a de­ci­sion in Eu­rope this sum­mer. It had $21.9 mil­lion in sales in the fi­nal three months of last year, the first full quar­ter it was on the mar­ket in the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER